Italy DNA vaccine market was valued at $28.92 million in 2025 and is projected to reach $42.37 million by 2035, registering a CAGR of 4.0% during the forecast period from 2026 to 2035. Italy’s DNA vaccine market has gained momentum from the advancement of COVID-eVax, a plasmid DNA vaccine candidate developed by Takis S.r.l. in collaboration with Rottapharm Biotech. This development represents one of the most significant clinical DNA vaccine efforts within the country, reflecting a tangible progression from preclinical research into regulated human studies. In early 2021, the Italian Medicines Agency (AIFA) authorized the Phase I/II clinical trials for COVID-eVax, permitting evaluation of safety and immunogenicity in healthy adult volunteers. These trials are conducted across multiple Italian clinical sites and are designed to inform subsequent development phases. The structured clinical advancement underscores growing regulatory engagement and scientific capability in DNA vaccine research within Italy, setting a precedent for similar platforms.
Browse the full report description of “Italy DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/italy-dna-vaccines-market
Market Coverage
Key questions addressed by the report.
Italy DNA Vaccine Market Report Segment
By Type
By Technology
By Application
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/italy-dna-vaccines-market